US Executive Compensation Proxy SEC Filings — June 29, 2026

29-06-2026

Prestige Consumer Healthcare Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, highlighting fiscal 2026 as a defining year with the acquisition of Breathe Right® and strong free cash flow generation. However, the company faced macroeconomic volatility, geopolitical uncertainty, and supply chain disruptions in its eye care business. The board recommends electing six director nominees, approving executive compensation on an advisory basis, and ratifying PricewaterhouseCoopers LLP as auditor.

• · The 2026 Annual Meeting will be held on August 4, 2026 at 10:00 a.m. Eastern Daylight Time at the Company's offices in Tarrytown, New York.
• · Stockholders of record as of June 10, 2026 are entitled to vote.
• · The deadline to vote electronically or by telephone is 11:59 p.m. Eastern Daylight Time on August 3, 2026.
• · The proxy statement and proxy card are first being mailed or given to stockholders on or about June 29, 2026.
• · The company's fiscal year ended March 31, 2026.
• · The company experienced supply chain disruptions in its eye care business during fiscal 2026.

29-06-2026

Amneal Pharmaceuticals, Inc. filed a definitive proxy statement (DEFM14A) related to a merger or acquisition transaction. The filing details extensive post-closing obligations for the buyer, including employee retention and benefit continuity for at least one year, and a retention bonus program extending to September 1, 2028. The agreement also includes exclusivity provisions preventing the sellers from soliciting other acquisition proposals, and requires the buyer to obtain a representation and warranty insurance policy with a waiver of subrogation rights against the sellers except in cases of fraud.

• · The buyer must obtain a representation and warranty insurance policy (RW Policy) with a waiver of subrogation rights against the sellers except in cases of fraud.
• · The sellers are bound by an exclusivity clause prohibiting solicitation of other acquisition proposals until the earlier of agreement termination or closing.
• · The company must deliver audited financial statements for fiscal years ended December 31, 2025 and 2024 by May 31, 2026.
• · Retained employees will receive credit for prior service with the company for eligibility and vesting under post-closing benefit plans.
• · The company's 401(k) plan (Kashiv Biosciences, LLC 401(k) Plan) must be terminated or transferred prior to closing unless the buyer requests otherwise.

29-06-2026

Picard Medical, Inc. (PMI) filed a DEF 14A proxy statement for its 2026 Annual Meeting, proposing the election of four directors, an advisory vote on executive compensation, a vote on the frequency of future advisory votes (recommended annually), and approval of a reverse stock split within a 1-for-15 to 1-for-50 range. The reverse split is sought to address NYSE American non-compliance: stockholders' equity was approximately $3.8M as of Dec 31, 2025 (below the $4.0M minimum), and a deficit of approximately $(1.4)M as of Mar 31, 2026 (below the $2.0M minimum). The company has submitted a compliance plan with a deadline of November 8, 2027, but there is no assurance of regaining compliance, and the board may decide not to implement the split even if approved.

• · Four director nominees are all current directors: Richard Fang (Interim CEO, age 60), Sam Van (age 48, appointed Sep 2025), Joe Xiao (appointed June 2026, age 57), George Ye (appointed Sep 2025, age 50).
• · George Ye held senior roles at Edwards Lifesciences (Senior VP & GM Greater China, April 2019–Oct 2024) and Abbott Laboratories and Johnson & Johnson.
• · Sam Van previously served as a director and audit committee chair at Reed’s Inc. (since Oct 2024) and as a director at Relm Insurance Limited (since Jan 2019) and Phoenix Motor, Inc. (June 2022–May 2024).
• · The company received two NYSE American non-compliance notices: one on or before May 15, 2026 (Section 1003(a)(i)) and an earlier one for Section 1003(a)(ii).
• · The reverse stock split proposal includes a proportionate reduction in the number of authorized shares of capital stock.
• · The Board may abandon the reverse split at any time before it becomes effective, even if stockholders approve.
• · The advisory vote on executive compensation is non-binding, but the compensation committee will consider the outcome.

29-06-2026

M3-Brigade Acquisition V Corp. (MBAVW) is seeking shareholder approval at an extraordinary general meeting on July 17, 2026, for six proposals, including extending the deadline to complete a business combination by 12 months to August 2, 2027, and withdrawing up to $0.10 per outstanding Class A share from trust interest to fund operations. The company recently terminated its business combination agreement with ReserveOne, Inc. on June 12, 2026, due to market dynamics and investor feedback, and now needs additional time and working capital to find a new target. The board unanimously recommends voting 'FOR' all proposals, but the extension is critical to avoid liquidation.

• · The company's current deadline to complete a business combination is August 2, 2026, and without the extension, it would be forced to liquidate.
• · The Trust Interest Withdrawal Proposal allows withdrawal of up to $0.10 per outstanding Class A share from trust interest, with $1,000,000 for ordinary expenses and excess for accrued liabilities.
• · The Name Change Proposal would rename the company to Velos Acquisition I Corp. and change the sponsor to MI7 Sponsor, LLC.
• · The Fairness Opinion Proposal seeks to remove the requirement for a fairness opinion from the company's articles.
• · The Adjournment Proposal is conditional on insufficient votes for the other proposals.

29-06-2026

Blackstone Secured Lending Fund (BXSL) filed a DEF 14A proxy statement on June 29, 2026, for its virtual 2026 Annual Meeting of Shareholders to be held on September 24, 2026. The Board unanimously recommends voting FOR the election of two trustee nominees and FOR the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026. The filing includes standard governance matters but does not disclose any financial results or performance metrics.

• · The record date for voting is June 26, 2026.
• · Shareholders must have a 16-digit control number to participate in the virtual meeting.
• · Online check-in for the virtual meeting begins at 9:45 a.m. ET on September 24, 2026.
• · A quorum requires one third of shares entitled to vote.
• · The proxy statement and Annual Report for fiscal year ended December 31, 2025 are available at www.bxsl.com or www.sec.gov.
• · The Board is not aware of any other business or nominees that may properly come before the meeting.

29-06-2026

Beeline Holdings, Inc. filed its DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders, to be held virtually via audio conference call on August 17, 2026. The Board unanimously recommends approval of all four proposals: election of directors, auditor ratification, an equity line of credit, and an adjournment proposal. Key named executive officers include Nicholas R. Liuzza, Jr. (CEO and Chairman) and Geoffrey Gwin, with compensation data provided for fiscal years 2023-2025.

• · The Annual Meeting will be held virtually via audio conference call on August 17, 2026 at 11:00 a.m. Eastern Time.
• · Record date for voting is June 18, 2026.
• · Proxy materials first mailed on or about July 2, 2026.
• · Stockholders can vote via internet, email, mail, fax, or during the audio conference call.
• · Internet voting deadline is August 16, 2026 at 11:59 p.m. ET.
• · The four proposals are: Election of Directors, Auditor Ratification, Equity Line of Credit, and Adjournment Proposal.
• · The Board unanimously recommends approval of all proposals.
• · Company address: 188 Valley Street, Suite 225, Providence, RI, 02909.
• · Phone number: 888-810-5760.

29-06-2026

AnaptysBio, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held on August 11, 2026. Key proposals include electing two Class III directors, ratifying KPMG LLP as the independent auditor for the fiscal year ending June 30, 2027, an advisory vote on executive compensation, and an amendment to the 2017 Equity Incentive Plan. No financial results are disclosed in this filing, and no period-over-period comparisons are provided.

29-06-2026

Compass Digital Acquisition Corp. is seeking shareholder approval for a fifth extension (to January 20, 2027) to complete its business combination with KMC, as the current deadline of July 20, 2026 is unlikely to be met. As of June 26, 2026, the trust account held approximately $1.31 million, equating to about $11.82 per public share, while the stock closed at $11.00 on the same date. If the extension is not approved, the company will be forced to liquidate, with public shareholders receiving their pro rata trust distribution and warrants expiring worthless.

• · The meeting is scheduled for July 15, 2026, at 12:00 p.m. Eastern Time.
• · Shareholders must tender shares for redemption at least two business days before the meeting (by July 13, 2026).
• · Approval of the Fifth Extension requires a special resolution (affirmative vote of at least two-thirds of votes cast).
• · Approval of the Adjournment Proposal requires a simple majority of votes cast.
• · If the Fifth Extension is approved, the board may unilaterally decide to liquidate at any time before January 20, 2027.
• · The company has waived its right to withdraw up to $100,000 of interest for dissolution expenses, limiting it to $50,000.
• · Sponsors hold 2,110,122 Class B shares, 3,200,000 Class A shares, and 4,832,065 Private Placement Warrants.
• · As of the Record Date (June 24, 2026), there were 3,310,856 Class A and 2,110,122 Class B shares outstanding.
• · The trust account balance of $1.31 million as of June 26, 2026, may be significantly reduced by redemptions if the extension is approved.
• · No other business may be transacted at the meeting.

29-06-2026

Transportation & Logistics Systems, Inc. (TLSS) is seeking stockholder approval for a 5,000-for-1 reverse stock split to increase its per-share trading price, enhance marketability, and attract institutional investors. As of May 31, 2026, the company had approximately 5.89 billion shares outstanding, which would be reduced to about 1.18 million shares if the split is implemented. However, the board acknowledges significant risks, including that the split may not increase the stock price over the long term, could decrease liquidity, and may lead to a lower overall market capitalization.

• · The reverse stock split ratio is 5,000-for-1.
• · The number of authorized shares of common stock will remain unchanged at 50,000,000,000 shares.
• · The par value of common stock remains $0.001 per share.
• · Fractional shares will be rounded up to the nearest whole share.
• · The conversion ratio of Series J Senior Convertible Preferred Stock will be adjusted from 100,000 shares of common stock per preferred share to 20 shares per preferred share.
• · The aggregate shares issuable upon conversion of Series J Preferred will drop from 11,042,400,000 to approximately 2,208,480 shares.
• · The board reserves the right to abandon the reverse stock split at any time before the effective time.
• · Stockholders do not have dissenters' or appraisal rights under Nevada law.
• · The reverse stock split is intended to be treated as a recapitalization for U.S. federal income tax purposes, generally resulting in no gain or loss recognition for U.S. holders.

29-06-2026

GNMA & US Government Target Maturity Fund for Puerto Rico Residents, Inc. filed a definitive proxy statement (DEF 14A) on June 29, 2026, for its 2026 Annual Meeting of Shareholders to be held virtually on July 30, 2026. The sole proposal is the election of four directors: Agustín Cabrer, Clotilde Pérez, Gabriel Pagán Pedrero (all Class I, term expiring 2029), and Jorge I. Vallejo (Class II, term expiring 2027). The Board recommends voting FOR ALL nominees. The filing includes standard procedural details and no financial performance data or period-over-period comparisons.

• · The record date for voting is June 12, 2026.
• · Shareholders must register by July 28, 2026, to attend the virtual meeting.
• · The Fund's audited financial statements for the fiscal year ended March 31, 2026, are included in the Annual Report mailed to shareholders.
• · A quorum requires holders of more than one-half of outstanding shares.
• · Directors are elected by a plurality of votes cast.

29-06-2026

Texas Mineral Resources Corp. (TMRC) is proposing to be acquired by USA Rare Earth, Inc. (USAR) through a successive merger structure, with TMRC shareholders receiving a fractional share of USAR common stock for each TMRC share held. The transaction is valued based on the exchange of approximately 3,823,328 USAR shares, with USAR stock closing at $24.64 per share on June 18, 2026. The TMRC Board recommends voting 'FOR' the merger, which requires majority approval from outstanding TMRC shares; a special meeting is scheduled for July 28, 2026.

• · TMRC's common stock is listed on Nasdaq under ticker USAR (though this appears to be a typo—USAR is the acquirer's ticker; TMRC likely trades under TMRX).
• · The special meeting will be held virtually on July 28, 2026 at 10:00 a.m. Eastern Time.
• · Record date for stockholder voting entitlement is June 2, 2026.
• · Completion of the merger is conditioned on approval by holders of a majority of outstanding TMRC shares.
• · The proxy statement/prospectus is dated June 29, 2026 and first mailed on or about that date.
• · TMRC’s principal office address is 527 21st Street, #44, Galveston, TX 77550 (business address previously listed as 539 El Paso Street, Sierra Blanca, TX 79851).

29-06-2026

Tax-Free Fixed Income Fund VI for Puerto Rico Residents, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Shareholders to be held virtually on July 30, 2026. The sole proposal is the election of four directors: Gabriel Pagán Pedrero (Class I, term expiring 2027), Jorge I. Vallejo (Class II, term expiring 2028), Luis M. Pellot (Class III, term expiring 2029), and Carlos Nido (Class III, term expiring 2029). The Board of Directors recommends a vote FOR ALL nominees. The record date is June 12, 2026, and the proxy statement was first mailed on or about June 29, 2026.

• · The 2026 Annual Meeting will be held virtually on July 30, 2026 at 11:30 a.m. Atlantic Standard Time.
• · Shareholders of record as of June 12, 2026 are entitled to vote.
• · Shareholders must register by July 28, 2026 to attend the virtual meeting.
• · The proxy statement and annual report for the fiscal year ended March 31, 2026 were mailed to shareholders on or about June 29, 2026.
• · A quorum requires more than one-half of outstanding shares represented virtually or by proxy.
• · Directors are elected by a plurality of votes cast; if only the four nominees stand, each needs at least one vote in favor.

29-06-2026

Theriva Biologics, Inc. filed its DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders to be held on August 3, 2026 at its Barcelona facility. The filing contains compensation tables and voting items, including setting of proxy voting recommendations by the Board of Directors.

• · Annual Meeting date: August 3, 2026 at 3:30 p.m. local time
• · Meeting location: Carrer Torrent de Can Ninou, naus 5-6, 08150 - Parets del Vallès (Barcelona), Spain
• · Record date and detailed proposals not included in provided text extract
• · XEBR tags reference compensation data for fiscal years 2023, 2024, and 2025 including equity awards, pension adjustments, and year-end fair values for named executive officers and non-PEO NEOs

29-06-2026

Aura Biosciences, Inc. filed a definitive proxy statement (DEF 14A) on June 29, 2026, for a Special Meeting of Stockholders to be held virtually on August 5, 2026. The meeting seeks stockholder approval to increase authorized common shares from 150,000,000 to 500,000,000 and to approve Amendment No. 1 to the 2021 Stock Option and Incentive Plan. As of the record date of June 12, 2026, there were 103,436,416 shares outstanding, and no preferred shares were outstanding.

• · The Special Meeting will be held virtually on August 5, 2026 at 9:30 a.m. Eastern Time via www.virtualshareholdermeeting.com/AURA2026SM.
• · Stockholders of record at the close of business on June 12, 2026 are entitled to vote.
• · The company is an 'emerging growth company' under the JOBS Act and provides scaled disclosure.
• · Proxy materials were first mailed to stockholders on or about June 29, 2026.

29-06-2026

Rocky Mountain Chocolate Factory, Inc. filed its definitive proxy statement (DEF 14A) on June 29, 2026, for the annual meeting scheduled for August 3, 2026. The filing includes detailed compensation disclosures for three former principal executive officers (PEOs) and non-PEO NEOs, showing significant variability in equity award adjustments across fiscal years 2024-2026. Notably, PEO 2 had a negative total equity adjustment of -$385,839 in fiscal 2025 due to forfeited awards, while PEO 3 had a positive adjustment of $43,743 in fiscal 2026, reflecting mixed compensation outcomes.

• · PEO 2 had a negative equity adjustment of -$385,839 in FY2025, driven by a -$328,919 fair value of forfeited awards and a -$2,920 change in fair value of vested awards.
• · PEO 3 had a positive equity adjustment of $43,743 in FY2026, including $41,830 year-over-year change in outstanding unvested awards and $1,913 change in fair value of vested awards.
• · Average non-PEO NEOs had a negative equity adjustment of -$59,246 in FY2025, primarily due to -$82,734 in forfeited awards.
• · No equity awards were granted or vested for PEO 1 in any of the three fiscal years presented.
• · The annual meeting is scheduled for August 3, 2026.

29-06-2026

Oportun Financial Corp filed its definitive proxy statement (DEF 14A) on June 29, 2026, for the annual meeting scheduled for August 11, 2026. The meeting will be held virtually, and stockholders will vote on four proposals: election of one Class I director, ratification of Deloitte & Touche LLP as auditor, an advisory vote on executive compensation, and an advisory vote on the frequency of future say-on-pay votes. As of the record date of June 16, 2026, there were 45,902,567 shares of common stock outstanding.

• · The annual meeting will be held virtually on August 11, 2026 at 8:00 a.m. Pacific time.
• · Stockholders of record as of June 16, 2026 are entitled to vote.
• · Proposals include: election of one Class I director, ratification of Deloitte & Touche LLP, advisory vote on executive compensation, and advisory vote on frequency of future say-on-pay votes.
• · Broker non-votes are expected on non-routine matters (Proposals 1, 3, and 4) if instructions are not provided.
• · The quorum requirement is 22,951,284 shares (a majority of outstanding shares).

29-06-2026

CreditRiskMonitor.com Inc. filed its definitive proxy statement (DEF 14A) on June 29, 2026, for the annual meeting of stockholders. The filing includes executive compensation details and is accompanied by the 2025 Annual Report on Form 10-K. No specific financial results or material corporate events are disclosed in this filing.

• · The proxy statement is for the year ended December 31, 2025.
• · The filing includes a copy of the Annual Report on Form 10-K (excluding exhibits).
• · Exhibits may be furnished upon payment of reasonable expenses.